Results 191 to 200 of about 7,355,151 (266)

Integrated m6A methylome and transcriptome profiling of mRNAs and lncRNAs in nasal mucosal epithelial cells of allergic rhinitis patients undergoing allergen-specific immunotherapy. [PDF]

Clin Epigenetics
Lai S, Yu L, Sun L, Zheng H, Lu T, Li Z, Chen C, Wei Y, Wen W.   +8 more
europepmc   +1 more source

Update on Non‐Biological and RNA‐Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules: An EAACI Position Paper

Allergy, Volume 81, Issue 9, Page 3039-3070, September 2026.
ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
Franziska Roth‐Walter, Ian M. Adcock, Cristina Benito‐Villalvilla, Rodolfo Bianchini, Leif Bjermer, Gaetano Caramori, Luigi Cari, Kian Fan Chung, Zuzana Diamant, Ibon Eguiluz‐Gracia, Edward F. Knol, Milos Jesenak, Francesca Levi‐Schaffer, Giuseppe Nocentini, Liam O'Mahony, Oscar Palomares, Frank Redegeld, Milena Sokolowska, Betty Van Esch, Marco Zurlo, Cristiana Stellato   +20 more
wiley   +1 more source

Prospective Evaluation of Specific IgE Profile and Quality-of-Life During Allergen-Specific Immunotherapy with House Dust Mite: A Pilot Study. [PDF]

Medicina (Kaunas)
Sakalauskaite S, Pilkyte L, Gasiuniene E, Gradauskiene B.   +3 more
europepmc   +1 more source

Type‐2‐Inflammatory‐Diseases Share Comorbidities, Molecular Signatures, IL4/IL13 Genetics, and Response to IL4/IL13 Blockade

Allergy, Volume 81, Issue 9, Page 3345-3360, September 2026.
Studies suggest that type 2 inflammatory diseases are driven by overactivation of the IL4/IL13 pathway, manifesting differently in distinct tissues. We performed quantitative analyses using several large independent datasets to explore the interrelation of type 2 inflammatory diseases based on co‐prevalence, genetic predispositions, and transcriptomic ...
Jennifer D. Hamilton, Manuel A. R. Ferreira, Wei Keat Lim, Carlo Sidore, Matthew F. Wipperman, Wenzhen Ge, Xue Song, Changming Xia, Julie E. Horowitz, Andrea T. Hooper, Sara C. Hamon, Jennifer Maloney, Jamie M. Orengo, Zhen Chen, Stephanie Amato Ricci, Bolanle Akinlade, Aris Baras, Gary Herman, Brandy L. Bennett, George D. Yancopoulos   +19 more
wiley   +1 more source

Efficacy evaluation of allergen-specific immunotherapy in children with asthma: a systematic review and meta-analysis. [PDF]

BMC Pulm Med
Wu K, Wu S, Wang L.
europepmc   +1 more source

Reply to: Malik MMUD on Early and Sustained Improvements in Sense of Smell With Tezepelumab Treatment in Patients With Chronic Rhinosinusitis With Nasal Polyps (WAYPOINT)

International Forum of Allergy &Rhinology, Volume 16, Issue 9, Page 1060-1061, September 2026.
Joaquim Mullol, Joseph K. Han, Tanya M. Laidlaw, Claire Hopkins, Anju T. Peters, Oliver Pfaar, Martin Desrosiers, Stella E. Lee, Andrew P. Lane, Claudia Chen, Yun Chon, Sandhia S. Ponnarambil, Andrew Foster, Andrew W. Lindsley, Christopher S. Ambrose   +14 more
wiley   +1 more source

MAIT Cells Suppress IgE‐Mediated Asthma via IFNγ‐Dependent B Cell Regulation

Allergy, Volume 81, Issue 9, Page 3236-3249, September 2026.
In this study, we demonstrate that MAIT cell antagonism during sensitization and challenge with HDM worsens the development of airway hyperreactivity without effects on type 2 or 17 associated cytokine production or lung inflammation. Rather, MAIT cells appear to regulate HDM‐induced asthma through direct inhibition of IgE production.
Angela M. Cannata, Jaclyn W. McAlees, Julie M. Hargis, Archana Shankar, Shouxiong Huang, Senad Divanovic, Ian P. Lewkowich   +6 more
wiley   +1 more source

Anti-IgE therapy versus allergen-specific immunotherapy for food allergy: weighing the pros and cons. [PDF]

Front Immunol
Kulis MD, Humphrey JR, Krempski JW, Kim EH, Smeekens JM.   +4 more
europepmc   +1 more source

Remission in Global Airway Diseases: EUFOREA Consensus Paper

Allergy, Volume 81, Issue 9, Page 3146-3156, September 2026.
ABSTRACT The therapeutic goal in chronic airway diseases is shifting from symptom control to disease remission. Disease‐modifying therapies, including biologics and allergen immunotherapy, have made remission achievable in patients with severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), or allergic rhinitis (AR).
J. Christian Virchow, Xander Bertels, Vibeke Backer, Benjamin S. Bleier, Marco Caminati, Diego M. Conti, Eugenio De Corso, Mina Gaga, Valerie J. Lund, Corrado Pelaia, Anju T. Peters, Glenis K. Scadding, Martin Wagenmann, Riyad O. Al‐Lehebi, Guy G. Brusselle, Philippe Gevaert, Liam G. Heaney, Stella E. Lee, Florence Schleich, Frederik Trinkmann, Peter W. Hellings, Wytske J. Fokkens, Paola Rogliani   +22 more
wiley   +1 more source

Transdermal Allergen-Specific Immunotherapy Using a Biodegradable Microneedle Array Patch in a Murine Model of Peanut Anaphylaxis. [PDF]

Allergy Asthma Immunol Res
Yun HJ, Oh EY, Kim H, Kim DJ, Kim SH, Shin Y, Kim J, Lee KH, Jhun J, Cho ML, Jeong DH, Jeong KY, Park JW.   +12 more
europepmc   +1 more source